Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On April27, 2017, Sarepta Therapeutics, Inc. issued a press
release announcing its results of operations and financial
condition for the three months ended March31, 2017. A copy of the
press release is furnished as Exhibit 99.1 and is incorporated
herein by reference.
The information in this report furnished to Item2.02,
including Exhibit 99.1 attached hereto, shall not be deemed filed
for the purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section. It may only be incorporated by
reference in another filing under the Exchange Act or the
Securities Act of 1933, as amended, if such subsequent filing
specifically references the information furnished to Item2.02 of
this report.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit Number |
Description |
|
| 99.1 | Press release dated April 27, 2017. |
About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Recent Trading Information
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed its last trading session down -0.14 at 34.72 with 2,836,597 shares trading hands.